Liên minh châu Âu cán mốc tiêm 200 triệu liều vaccine ngừa COVID-19

Theo số liệu chính thức do các cơ quan y tế quốc gia cung cấp, tính đến ngày 18/5, ít nhất 200 triệu liều vaccine ngừa COVID-19 đã được tiêm cho người dân tại Liên minh châu Âu (EU). Cột mốc quan trọng này chứng tỏ EU sẽ có thể đạt mục tiêu tiêm đủ vaccine cho 70% người trưởng thành, tức là khoảng 255 triệu người trên tổng số 448 triệu dân, vào cuối tháng Bảy.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Hy vọng mới trong điều trị ung thư tuyến tụy

Hy vọng mới trong điều trị ung thư tuyến tụy

Thế giới
(Baothanhhoa.vn) - Một loại thuốc thử nghiệm có tên Daraxonrasib đang mở ra hy vọng mới trong điều trị ung thư tuyến tụy, sau khi kết quả nghiên cứu công bố trên tạp chí y khoa New England Journal of Medicine cho thấy thuốc có thể giúp kéo dài gấp đôi thời gian sống...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh